Brief Title |
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
|
Official Title |
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
|
Principal Investigator |
Nanda, Rita
|
Brief Summary |
This randomized phase III trial studies how well pembrolizumab works in treating
triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere
with the ability of tumor cells to grow and spread.
|
Gender |
All
|
Ages |
18 Years
|
Enrollment |
1000
|
Accepts Healthy Volunteers |
No
|
Lead Sponsor |
National Cancer Institute (NCI)NIH
|
Collaborator |
|
Study Design |
|
Study Phase |
Phase 3
|
Study Type |
Interventional
|
Contact Name |
Gary E. Goodman
|
Contact Phone |
1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
|
Condition |
Estrogen Receptor Negative
|